EGFR and non-small cell lung carcinoma: This retrospective study analysed data from all patients with advanced NSCLC and EGFR activating mutation treated with single-agent TKI in the first-line setting in the last 5 years at our Institutions, along with all consecutive patients treated with first-line osimertinib at Mauriziano Hospital.